Results 261 to 270 of about 764,478 (294)

The mecillinam resistome in <i>Klebsiella pneumoniae</i>: how resistance to a one-target β-lactam triggers a diversity of responses. [PDF]

Antimicrob Agents Chemother
Royer M, Cabanel N, Gutierrez A, Royer G, Barraud O, Naas T, Rosinski-Chupin I, Loverdo C, Glaser P.   +8 more
europepmc   +1 more source

β-Lactam Ylidenes: An Overlooked Class of N-Heterocyclic Carbenes. [PDF]

Chemistry
Karl L, Deißenbeck D, Meisner J, Ganter C.   +3 more
europepmc   +1 more source

Aminoglycoside versus β-lactam treatment for urosepsis-a retrospective cohort study. [PDF]

JAC Antimicrob Resist
Cahan A, Peleg R, Sorek N, Brosh-Nissimov T.   +3 more
europepmc   +1 more source

Genetically Engineered Yeast for Enhanced Biodegradation of Β-lactam Antibiotics. [PDF]

Appl Biochem Biotechnol
Pohl C, Rau C, Schuster L, Gutbier U, Beil S, Lehmann K, Börnick H, Ostermann K, Stolte S.   +8 more
europepmc   +1 more source

One-step degradation of 4 classes of β-lactam using β-lactamase enzyme cocktail. [PDF]

Sci Rep
Lin J, Wang T, Zhou Y, Cheng T, Liu H, Chen X, Luo W, Liu Q, Chu Y, Wang X, Xie F, Sha J, Song T.   +12 more
europepmc   +1 more source

The Road to Avibactam: The First Clinically Useful Non-β-Lactam Working Somewhat Like a β-Lactam

Future Medicinal Chemistry, 2016
Avibactam, which is the first non-β-lactam β-lactamase inhibitor to be introduced for clinical use, is a broad-spectrum serine β-lactamase inhibitor with activity against class A, class C, and, some, class D β-lactamases.
David Y Wang, Martine I Abboud, Marios S Markoulides   +2 more
exaly   +3 more sources